Impact Biomedical Inc. (IBO) Stock Price & Analysis
Impact Biomedical Inc. (IBO) rose 2.25% to USD 0.44 as of July 25, 2026 at 09:12 UTC, according to Nexqual real-time market data.
IBO last closed at USD 0.43; the session ranged USD 0.43–0.45 on volume of 13,235 shares. Market capitalization is $47.44M, with a 52-week range of USD 0.37–0.83 (ASE). Source: Nexqual, July 25, 2026 at 09:12 UTC.
Key Statistics (as of July 25, 2026 at 09:12 UTC)
| Price | USD 0.44 |
|---|---|
| Change | ▲ 2.25% (up) |
| Previous Close | USD 0.43 |
| Open | USD 0.43 |
| Day Range | USD 0.43 – 0.45 |
| 52-Week Range | USD 0.37 – 0.83 |
| Volume | 13,235 shares |
| Market Cap | $47.44M |
| Exchange | ASE |
Technical Analysis (IBO)
Nexqual's technical model rates IBO "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 09:12 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.12 (neutral) |
| vs SMA50 | Below (USD 0.51) |
| MACD | -0.02 (negative) |
Analyst Ratings (IBO)
Wall Street analysts rate IBO "None", per Nexqual as of July 25, 2026 at 09:12 UTC.
| Consensus Rating | None |
|---|
Earnings (IBO)
Source: Nexqual, July 25, 2026 at 09:12 UTC.
Financials & Fundamentals (IBO)
| Total Revenue | $39,000 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -32700.00% |
| Profit Margin | +0.00% |
| ROE | -119.66% |
| Debt / Equity | 7.5 |
| Current Ratio | 0.22 |
| Total Cash | $20,000 |
| Total Debt | $1.10M |
| Free Cash Flow | $-775,375 |
Source: Nexqual, July 25, 2026 at 09:12 UTC.
Financial Health Score (IBO)
Nexqual rates Impact Biomedical Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 09:12 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $20K cash vs $1M debt |
| Cash Flow | Weak — FCF negative: -$775K, burning cash |
| Efficiency | Critical — ROE -120%, ROA -18.7% |
Ownership (IBO)
| Insider Ownership | +89.02% |
|---|---|
| Institutional Ownership | +3.45% |
| Shares Outstanding | 107.82M |
| Float | 11.49M |
| Short % of Float | +4.75% |
Source: Nexqual, July 25, 2026 at 09:12 UTC.
Leadership (IBO)
Impact Biomedical Inc. is led by Frank D. Heuszel Esq. (age 68), Chairman & CEO, per Nexqual as of July 25, 2026 at 09:12 UTC.
| Chairman & CEO | Frank D. Heuszel Esq. (age 68) |
|---|---|
| CFO, Secretary & Treasurer | Todd D. Macko (age 52) |
| Chief Operating Officer | Mark J. Suseck (age 63) |
Major Backers & Investors (IBO)
Notable institutional backers of Impact Biomedical Inc. include Fidelity, according to Nexqual as of July 25, 2026 at 09:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.89% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.89% |
| Geode Capital | 1.11% |
| State Street | 0.56% |
| BlackRock | 0.24% |
| Northern Trust | 0.23% |
Source: Nexqual, July 25, 2026 at 09:12 UTC.
From Impact Biomedical Inc.'s Latest SEC 10-K Filing (filed 2026-03-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Chemia is a leading developer and manufacturer of fragrances and flavors.   In addition to Chemia, IBO is actively seeking potential partners for further development and commercialization of 3F worldwide, given the broad application of this technology.   Composition patents have been issued in the U.S. and are pending in other countries.   Equivir   Equivir/Equivir G technology is a novel blend of FDA Generally Recognized as Safe (GRAS) eligible polyphenols (e.g.
- In order to protect our proprietary technology and processes, we also rely in part on confidentiality and intellectual property assignment agreements with our corporate partners, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors.
- The protective steps we have taken may be inadequate to deter our competitors from using our proprietary information.
- Despite our efforts to protect our proprietary rights, unauthorized parties may copy aspects of our services or technology, obtain and use information, marks, or technology that we regard as proprietary, or otherwise violate or infringe our intellectual property rights.
Partnerships
- However, this risk would be mitigated in the event the Company is successful entering into a co-development agreement with a pharma partner for late stage clinical development.
- In addition, our licensors may terminate their agreements with us in the event we breach the applicable license agreement and fail to cure the breach within a specified period of time.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XHLD | TEN Holdings, Inc. | USD 1.86 | ▼ 11% |
| PLRZ | Polyrizon Ltd. | USD 14.68 | ▲ 2.02% |
| OSRH | OSR Health, Inc. | USD 0.42 | ▼ 3.64% |
| TNON | Tenon Medical, Inc. | USD 0.19 | ▼ 3.65% |
| GRML | Greenland Mines Ltd | USD 0.19 | ▼ 13.24% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 09:12 UTC. This page is informational and not investment advice.